Skip to main content
SpringerLink
Log in

The Authors’ Reply

  • Correspondence
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kelly WN, Arellano FM, Barnes J, et al. Guidelines for submitting adverse event reports for publication. Drug Saf 2007; 30(5): 367–73

    Article  PubMed  Google Scholar 

  2. Aronson JK. Anecdotes as evidence. BMJ 2003 Jun 21; 326(7403): 1346

    Article  PubMed  Google Scholar 

  3. Auriche M, Bertrand P, Blay N, et al. Good practices of publication of clinical cases of pharmacovigilance: comments, Groupe de Travail sur les Bonnes Pratiques de Publication de Cliniques en Pharmacovigilance: commentary in French]. Therapie 1997 Mar–Apr; 52(2): 123–7

    PubMed  CAS  Google Scholar 

  4. Moore N, Montero D, Coulson R, et al. The single case format: proposal for a structured message for the telematic transmission of information on individual case reports in pharmacovigilance. Pharmacoepidemiol Drug Saf 1994; 3: 157–62

    Article  Google Scholar 

  5. Venulet J. Informativity of adverse drug reactions data in medical publications. Drug Inf J 1985; 19: 357–65

    Google Scholar 

  6. Venulet J, Blattner R, von Bulow J, et al. How good are articles on adverse drug reactions? Br Med J (Clin Res Ed) 1982 Jan 23; 284(6311): 252–4

    Article  CAS  Google Scholar 

  7. Haramburu F, Begaud B, Pere JC, et al. Role of medical journals in adverse drug reaction alerts. Lancet 1985 Sep 7; 2(8454): 550–1

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors have no conflicts of interest that are directly relevant to the content of this letter.

Author information

Authors and Affiliations

  1. William N. Kelly Consulting, Inc., Oldsmar, Florida, USA

    William Kelly

  2. Université Victor Segalen, Bordeaux, France

    Nicholas Moore

  3. Goldsmith Pharmacovigilance and Systems, New York, New York, USA

    David I. Goldsmith

  4. The Degge Group, Ltd., Arlington, Virginia, USA

    Judith K. Jones

  5. Centre Hospitalier Universitaire, Reims, France

    Thierry Trenque

  6. Netherlands Pharmacovigilance Centre, ’s-Hertogenbosch, the Netherlands

    Eugene van Puijenbroek

Authors
  1. William Kelly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicholas Moore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David I. Goldsmith
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Judith K. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thierry Trenque
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eugene van Puijenbroek
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kelly, W., Moore, N., Goldsmith, D.I. et al. The Authors’ Reply. Drug-Safety 31, 356–357 (2008). https://doi.org/10.2165/00002018-200831040-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831040-00010

Keywords

Search

Navigation